#johnson-and-johnson

Johnson & Johnson

Johnson & Johnson (JNJ) earnings, pharmaceutical and MedTech segment analysis, and Open Ledger coverage

Johnson & Johnson Q3 2026 Earnings: $0.09 EPS on $25.4B Sales as a $5.5B Talc Charge Meets a Guidance Raise

J&J Q3 2026: $25.4B sales (+5.9%) but $0.09 EPS after a $5.5B talc charge; adjusted EPS $2.59 as guidance rises to $101.2B.

Mike Thrift